Published in Prim Care Companion J Clin Psychiatry on August 01, 2002
Tools to improve differential diagnosis of bipolar disorder in primary care. Prim Care Companion J Clin Psychiatry (2010) 0.81
A comparative study on psycho-socio-demographic and clinical profile of patients with bipolar versus unipolar depression. Indian J Psychiatry (2016) 0.77
Treating bipolar disorder in the primary care setting: the role of aripiprazole. Prim Care Companion J Clin Psychiatry (2009) 0.75
Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry (1994) 48.75
The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA (1989) 12.07
The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry (1993) 9.09
Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry (2000) 5.21
Health-related quality of life in primary care patients with mental disorders. Results from the PRIME-MD 1000 Study. JAMA (1995) 4.40
Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry (2002) 4.24
One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry (1988) 4.13
Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Arch Gen Psychiatry (1995) 3.92
The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J Affect Disord (1994) 3.15
A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry (2000) 2.88
Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord (2000) 2.81
Bipolar disorders in a community sample of older adolescents: prevalence, phenomenology, comorbidity, and course. J Am Acad Child Adolesc Psychiatry (1995) 2.78
Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry (1995) 2.53
The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord (1998) 2.47
Cost-effectiveness of a collaborative care program for primary care patients with persistent depression. Am J Psychiatry (2001) 2.35
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry (2000) 2.34
"Cade's disease" and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Can J Psychiatry (2002) 2.32
Psychiatric diagnosis: are clinicians still necessary? Compr Psychiatry (1983) 2.20
Criteria for the "soft" bipolar spectrum: treatment implications. Psychopharmacol Bull (1987) 2.16
On the nature of depressive and anxious states in a family practice setting: the high prevalence of bipolar II and related disorders in a cohort followed longitudinally. Compr Psychiatry (1997) 2.13
Switching from 'unipolar' to bipolar II. An 11-year prospective study of clinical and temperamental predictors in 559 patients. Arch Gen Psychiatry (1995) 2.11
A novel augmentation strategy for treating resistant major depression. Am J Psychiatry (2001) 2.05
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry (2002) 2.01
Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry (1994) 1.96
Strategies to reduce misdiagnosis of bipolar depression. Psychiatr Serv (2001) 1.93
Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry (2001) 1.60
A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry (1999) 1.57
Antidepressant-induced mania in bipolar patients: identification of risk factors. J Clin Psychiatry (2001) 1.53
The bipolar spectrum: a clinical reality in search of diagnostic criteria and an assessment methodology. J Affect Disord (1999) 1.50
Children of parents with bipolar disorder: a metaanalysis of risk for mental disorders. Can J Psychiatry (1997) 1.47
Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry (1999) 1.40
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry (2001) 1.35
A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry (2000) 1.28
Can depression treatment in primary care reduce disability? A stepped care approach. Arch Fam Med (2001) 1.26
The depressive spectrum: diagnostic classification and course. J Affect Disord (1997) 1.16
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry (2001) 1.12
A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry (2002) 1.10
Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice. J Affect Disord (1997) 1.09
Prevalence of bipolar II disorder in outpatient depression: a 203-case study in private practice. J Affect Disord (1997) 1.06
Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord (2000) 1.05
Rapid cycling manic depressive patients. Compr Psychiatry (1978) 1.03
Teaching Family Physicians About Mood Disorders: A Procedure Suite for Behavioral Medicine. Prim Care Companion J Clin Psychiatry (1999) 1.01
Heritable factors in the severity of affective illness. Biol Psychiatry (1976) 1.00
The "switch process" in manic-depressive illness. II. Relationship to catecholamines, REM sleep, and drugs. Arch Gen Psychiatry (1972) 1.00
Is 4 days the minimum duration of hypomania in bipolar II disorder? Eur Arch Psychiatry Clin Neurosci (2001) 1.00
The Zurich Study. X. Hypomania in a 28- to 30-year-old cohort. Eur Arch Psychiatry Clin Neurosci (1991) 0.96
The Expert Consensus Guidelines for treating depression in bipolar disorder. J Clin Psychiatry (1998) 0.94
Lithium. Current status in psychiatric disorders. Drugs (1993) 0.93
Diagnostic reliability of the history of hypomania in bipolar II patients and patients with major depression. Compr Psychiatry (1994) 0.89
[Frequency and clinical aspects of bipolar II disorder in a French multicenter study: EPIDEP]. Encephale (2001) 0.88
Bipolar II: the most common bipolar phenotype? Am J Psychiatry (1993) 0.88
Lithium in the treatment of depression. Am J Psychiatry (1976) 0.86
Substance abuse and bipolar comorbidity. Psychiatr Clin North Am (1999) 0.85
The temperamental borders of affective disorders. Acta Psychiatr Scand Suppl (1994) 0.85
Latency and episodes before treatment: response to lithium maintenance in bipolar I and II disorders. Bipolar Disord (1999) 0.83
Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry (1998) 0.83
Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: results of an open-label study. J Clin Psychiatry (1999) 0.82
Sustained remission with lamotrigine augmentation or monotherapy in female resistant depressives with mixed cyclothymic-dysthymic temperament. J Affect Disord (2005) 0.82
Antiepileptic drugs for the acute and maintenance treatment of bipolar disorder. Harv Rev Psychiatry (2001) 0.82
Treatment-refractory depression: definitions and characteristics. Depress Anxiety (1997) 0.81
Prevalence of bipolar II disorder in atypical depression. Eur Arch Psychiatry Clin Neurosci (1999) 0.81
Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry (1993) 0.80
Gabapentin as an adjunctive treatment in bipolar disorder. J Affect Disord (1999) 0.78
Antiepileptic drugs for the treatment of panic disorder. Neuropsychobiology (1993) 0.76
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry (2007) 1.54
An excitement subscale of the Positive and Negative Syndrome Scale. Schizophr Res (2004) 1.07
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry (2007) 0.99
Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol (2009) 0.92
An analysis of correlations among four outcome scales employed in clinical trials of patients with major depressive disorder. Ann Gen Psychiatry (2009) 0.87
Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study. Int Clin Psychopharmacol (2008) 0.85
The Metabolic Syndrome in Patients With Severe Mental Illnesses. Prim Care Companion J Clin Psychiatry (2004) 0.85
Onset of activity and time to response on individual CAPS-SX17 items in patients treated for post-traumatic stress disorder with venlafaxine ER: a pooled analysis. Int J Neuropsychopharmacol (2008) 0.82
Metabolic Issues With Atypical Antipsychotics in Primary Care: Dispelling the Myths. Prim Care Companion J Clin Psychiatry (2003) 0.81
The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol (2008) 0.80
A pooled analysis of gender and trauma-type effects on responsiveness to treatment of PTSD with venlafaxine extended release or placebo. J Clin Psychiatry (2008) 0.77
Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ER. CNS Spectr (2007) 0.76
A Perspective on the Primary Care of Patients With Behavior, Mood, and Thought Disturbances: Clinical Applications of Olanzapine. Prim Care Companion J Clin Psychiatry (2001) 0.75
Olanzapine for the Treatment of Bipolar Disorder. Prim Care Companion J Clin Psychiatry (2002) 0.75
Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study. Ann N Y Acad Sci (2004) 0.75